Attached files
| file | filename |
|---|---|
| EX-32 - EXHIBIT 32 - AMERISOURCEBERGEN CORP | exhibit32section1350certif.htm |
| EX-31.2 - EXHIBIT 31.2 - AMERISOURCEBERGEN CORP | exhibit312rule13a-14a15dx1.htm |
| EX-31.1 - EXHIBIT 31.1 - AMERISOURCEBERGEN CORP | exhibit311rule13a-14a15dx1.htm |
| EX-23 - EXHIBIT 23 - AMERISOURCEBERGEN CORP | exhibit23consentofindepend.htm |
| EX-21 - EXHIBIT 21 - AMERISOURCEBERGEN CORP | exhibit21subsidiariesofthe.htm |
| 10-K - 10-K - AMERISOURCEBERGEN CORP | abc10-kxseptember302017.htm |
Exhibit 12
AmerisourceBergen Corporation
Computation of Ratio of Earnings to Fixed Charges
Fiscal Year Ended September 30, | ||||||||||||||||||||
(in thousands, except ratios) | 2017 | 2016 | 2015 | 2014 | 2013 | |||||||||||||||
Determination of earnings: | ||||||||||||||||||||
Income from continuing operations before income taxes | $ | 917,887 | $ | 1,390,910 | $ | 268,964 | $ | 669,863 | $ | 822,032 | ||||||||||
Add: | ||||||||||||||||||||
Loss (gain) on equity investments | 8,822 | (582 | ) | 30,833 | 172 | 113 | ||||||||||||||
Fixed charges (excluding capitalized interest) | 161,153 | 157,666 | 123,818 | 95,760 | 92,352 | |||||||||||||||
Amortization of capitalized interest | 1,676 | 1,676 | 1,676 | 1,676 | 1,635 | |||||||||||||||
Total earnings available for fixed charges | $ | 1,089,538 | $ | 1,549,670 | $ | 425,291 | $ | 767,471 | $ | 916,132 | ||||||||||
Fixed charges: | ||||||||||||||||||||
Interest expense | $ | 149,042 | $ | 144,349 | $ | 112,021 | $ | 84,475 | $ | 81,477 | ||||||||||
Capitalized interest | 1,269 | — | — | — | — | |||||||||||||||
Estimated interest portion of rent expense | 12,111 | 13,317 | 11,797 | 11,285 | 10,875 | |||||||||||||||
Total fixed charges | $ | 162,422 | $ | 157,666 | $ | 123,818 | $ | 95,760 | $ | 92,352 | ||||||||||
Ratio of earnings to fixed charges 1 | 6.7 | 9.8 | 3.4 | 8.0 | 9.9 | |||||||||||||||
____________________
1 For purposes of computing the above ratios:
• | Earnings include $914.4 million of charges for litigation settlements and accruals in the fiscal year ended September 30, 2017. |
• | Earnings include Warrants expense, a non-cash expense, of $140.3 million, $912.7 million, $422.7, and $90.1 million in the fiscal years ended September 30, 2016, 2015, 2014, and 2013, respectively. |
• | Loss (gain) on equity investments includes an impairment charge of $30.6 million in fiscal 2015 related to the Company's minority interest in a pharmaceutical wholesaler in Brazil. There was no such impairment charge recorded in the fiscal years ended September 30, 2017, 2016, 2014, or 2013, respectively. |